<div id="readability-page-1"><p>Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) dropped 6.4% during trading on Wednesday . The company traded as low as $0.3084 and last traded at $0.3172. Approximately 486,137 shares were traded  during trading, a decline of 8% from the average daily volume of 529,920 shares. The stock had previously closed at $0.3390.</p><h2>Analyst Upgrades and Downgrades</h2><p>Several research firms recently weighed in on TVGN. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital dropped their price target on shares of Tevogen Bio from $10.00 to $5.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, November 20th. One investment analyst  has rated the stock with a Buy rating and one  has given a Sell rating to the company. According to MarketBeat.com, Tevogen Bio  has an average rating of &#34;Hold&#34; and an average target price of $5.00.</p><p><b>Read Our Latest Stock Analysis on Tevogen Bio</b></p><h2>Tevogen Bio Stock Performance</h2><p>The firm has a 50 day moving average of $0.38 and a two-hundred day moving average of $0.67. The stock has a market cap of $63.02 million, a P/E ratio of -1.67 and a beta of -0.79. </p><p>Tevogen Bio (NASDAQ:TVGN - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. </p><h2>Institutional Trading of Tevogen Bio</h2><p>A hedge fund recently raised its stake in Tevogen Bio stock. Bridgeway Capital Management LLC raised its stake in shares of  Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) by 66.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 82,500 shares of the company's stock after purchasing an additional 33,000 shares during the quarter. Bridgeway Capital Management LLC's holdings in Tevogen Bio were worth $65,000 as of its most recent filing with the SEC. </p><h2>Tevogen Bio Company Profile</h2> (Get Free Report)<p>Tevogen Bio plc <span>NASDAQ: TVGN<span></span></span> is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company's lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).  </p><p>In addition to its lead program in AML, Tevogen Bio's pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Tevogen Bio</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Do not delete, read immediately</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Tevogen Bio Right Now?</h2><p>Before you consider Tevogen Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.</p><p>While Tevogen Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TVGNW

TVGN

IBBQ

LABD

<p>Tevogen Bio (NASDAQ:TVGN) shares fell 6.4% to $0.3172 during trading, with a volume decline of 8% from the average. Analysts have mixed ratings, with Weiss Ratings maintaining a 'sell' and D. Boral Capital lowering the price target from $10 to $5 while rating it a 'buy'. The stock has a market cap of $63.02 million and a P/E ratio of -1.67. Tevogen Bio focuses on developing NK cell immunotherapies for cancer and viral diseases, with its lead candidate in clinical trials for AML.</p>

Tevogen Bio (NASDAQ:TVGN) Shares Down 6.4% - Here's Why